相似文献
1
Clinical Outcomes in Breast Cancer Patients with HER2-Positive, Node-Negative Tumors (≤3 cm).
Breast Care (Basel). 2022 Aug;17(4):356-363. doi: 10.1159/000522198. Epub 2022 Jan 27.
2
Small HER2-Positive Breast Cancer: Should Size Affect Adjuvant Treatment?
Clin Breast Cancer. 2015 Aug;15(4):277-84. doi: 10.1016/j.clbc.2014.12.012. Epub 2015 Jan 9.
3
High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers.
Int J Clin Oncol. 2012 Apr;17(2):131-6. doi: 10.1007/s10147-011-0269-4. Epub 2011 Jun 18.
4
Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Clin Breast Cancer. 2016 Dec;16(6):487-493. doi: 10.1016/j.clbc.2016.07.013. Epub 2016 Aug 1.
5
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
Cancer. 2011 Dec 15;117(24):5461-8. doi: 10.1002/cncr.26171. Epub 2011 Jun 16.
6
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Clin Transl Oncol. 2015 Nov;17(11):862-9. doi: 10.1007/s12094-015-1316-9. Epub 2015 Jun 24.
7
Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
Clin Cancer Res. 2019 Dec 15;25(24):7388-7395. doi: 10.1158/1078-0432.CCR-19-0463. Epub 2019 Sep 12.
8
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
Breast Cancer Res Treat. 2017 Apr;162(2):307-316. doi: 10.1007/s10549-017-4136-5. Epub 2017 Feb 2.
9
Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?
Ann Oncol. 2011 Jan;22(1):17-23. doi: 10.1093/annonc/mdq304. Epub 2010 Jun 20.
10
The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
Breast Cancer Res Treat. 2016 Jul;158(2):361-71. doi: 10.1007/s10549-016-3878-9. Epub 2016 Jun 29.
本文引用的文献
1
Anthracycline-containing carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial.
Ther Adv Med Oncol. 2021 Apr 20;13:17588359211009003. doi: 10.1177/17588359211009003. eCollection 2021.
2
Evolving standards of care and new challenges in the management of HER2-positive breast cancer.
CA Cancer J Clin. 2020 Sep;70(5):355-374. doi: 10.3322/caac.21634. Epub 2020 Aug 19.
3
The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?
Clin Breast Cancer. 2020 Dec;20(6):503-510. doi: 10.1016/j.clbc.2020.05.012. Epub 2020 May 27.
4
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
Breast Cancer. 2020 Jul;27(4):631-641. doi: 10.1007/s12282-020-01057-4. Epub 2020 Feb 14.
5
Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016).
Br J Cancer. 2019 Nov;121(11):904-911. doi: 10.1038/s41416-019-0612-5. Epub 2019 Nov 1.
6
Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
Clin Cancer Res. 2019 Dec 15;25(24):7388-7395. doi: 10.1158/1078-0432.CCR-19-0463. Epub 2019 Sep 12.
7
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.
Breast Cancer Res Treat. 2019 Aug;177(1):103-114. doi: 10.1007/s10549-019-05284-y. Epub 2019 May 27.
8
De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.
Cancer Chemother Pharmacol. 2019 Jun;83(6):1099-1104. doi: 10.1007/s00280-019-03836-z. Epub 2019 Apr 8.
9
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
J Clin Oncol. 2019 Aug 1;37(22):1868-1875. doi: 10.1200/JCO.19.00066. Epub 2019 Apr 2.
10
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6.
Zotero 插件